Skip to content

The effect of salbutamol in treatment of transient tachypnea of newborn

The effect of salbutamol in treatment of transient tachypnea of newborn

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014062518232N1
Enrollment
70
Registered
2014-08-07
Start date
2014-08-02
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transient tachypnea of newborn. Transient tachypnea of newborn

Interventions

Intervention 1: Intervention group : administration of one dose of Salbutamol (Asthalin, manufactured by CIPLA, INDIA) 0.15mililiter per kilogram of body weight, by nebulizer within 10 minutes.
Treatment - Drugs
Intervention group : administration of one dose of Salbutamol (Asthalin, manufactured by CIPLA, INDIA) 0.15mililiter per kilogram of body weight, by nebulizer within 10 minutes.
control group : to receive one dose of 0 .15 mililiter per kilogram of body weight of 0.9 % normal salin by nebulizer, with in ten minute.

Sponsors

Vice chancellor for research, Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Days to 1 Days

Inclusion criteria

Inclusion criteria: Inclusion criteria: The late preterm (gestational age of 34 – 37 weeks) and term (gestational ageof 37 -42 weeks) and post term (gestational age greater than 42 weeks) neonates with tachypnea (Respiratory Rate greater than 60 per minute) with or without respiratory distress within 6 hours of birth. Exclusion criteria: Pretem neonates (gestational age less than 34 weeks); neonates with history of asphyxia; birth trauma; meconium aspiration syndrome; congenital pneumonia; a history of chorioamnionitis or corticosteroids therapy in mother; gross congenital anomaly and neonates with tachycardia; arythmia; blood culture or CRP positive during treatment will be excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Tachypnea. Timepoint: before intervention; 30 minute, one, four, six hours later. Method of measurement: observation and record of respirtory rate per minute.

Secondary

MeasureTime frame
Respiratory Rate. Timepoint: before intervention; 30 minute, one, four, six hours later. Method of measurement: Observation and record.;Hart beat. Timepoint: before intervention; 30 minute, one, four, six hours later. Method of measurement: Observation and record of heart beat per minute.;Time of start feeding. Timepoint: Before intervention; 30minute, one, four, six hours later. Method of measurement: hour.;O2 requirement. Timepoint: Before intervention; 30 minute, one, four, six hours later. Method of measurement: per liter. per minute.;Duration of hospitalization. Timepoint: day. Method of measurement: day.;Retraction Score. Timepoint: Before intervention ;30 minute, one, four, six hours later. Method of measurement: Oservation and record on bases of SILVERMAN - ANDERSON Retraction Score.;Arterial Blood Gases. Timepoint: before intervention, and after intervention if necessary. Method of measurement: Blood sample.;Oxygen saturation percent. Timepoint: before intervention; 30 minute, one, four, six hours later. Method of measurement: observation and recod of oxygen saturation (percent).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHeydari Fatemeh

Babol University of Medical Sciences

dr.fatmeh_heydari@yahoo.comf.heydari@mubabol.ac.ir pediatrics_amirkola@yahoo.com+98 11 3235 2988

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026